eye on the ion

Rising innovation hub announces Chevron as first tenant and program partner

Chevron has signed on to have space in The Ion. The company will also be a program partner. Photo courtesy of The Ion

Chevron is the first tenant to sign a lease at The Ion, an innovation hub rising in Midtown Houston's former Sears building.

The Ion, a Rice Management Co. project expecting to premiere at 4201 Main St. in spring 2021, announced the new tenant and program partnership this week.

"Our first tenant at The Ion is one of the most recognizable brands in the world," says Ryan LeVasseur, managing director of Real Estate at Rice Management Co., in a news release. "We're thrilled to welcome Chevron into the Innovation District. They'll be the first of many companies, local startups, and business owners who make a home at and around The Ion as we continue to develop this groundbreaking, mixed-use space."

Chevron's Houston-based corporate investing arm, Chevron Technology Ventures, will be leading the space. The location can also be used by employees for networking, professional development and other opportunities within the innovation ecosystem.

"We are thrilled to support The Ion as a key component of Houston's growing innovation ecosystem," says Barbara Burger, president of CTV, in the release. "We have a long history in Houston with its role as the global energy capital. We believe The Ion will help to ensure that Houston retains that distinction and plays a leading role in the energy transition through innovation."

Founded in 1999, CTV has been an integral part of the Houston innovation ecosystem with its investment efforts and Catalyst Program. Recently, the group added two new startups to the accelerator.

CTV and Chevron in general have an existing relationship with The Ion and its team team, and Jan E. Odegard, interim executive director of The Ion, says he's excited for the relationship continue.

"By becoming our first tenant and a founding program partner, Chevron has shown it is committed to ensuring The Ion is Houston's premier destination for innovators, entrepreneurs, and academics to collaborate on workforce development, build tech-enabled businesses, and support the community," says Odegard in the release. "We're grateful to welcome such an esteemed organization to our space with which we share the same mission and values."

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News